Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 4.92
(1.76%)
USD 4.92
(1.76%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 35.17 Million USD | 5.57% |
| 2022 | 33.32 Million USD | -13.72% |
| 2021 | 38.62 Million USD | -32.27% |
| 2020 | 57.02 Million USD | 32.65% |
| 2019 | 42.98 Million USD | 120.83% |
| 2018 | 19.46 Million USD | 111.7% |
| 2017 | 9.19 Million USD | 2.52% |
| 2016 | 8.96 Million USD | 130.55% |
| 2015 | 3.89 Million USD | 427.11% |
| 2014 | 738.04 Thousand USD | -64.67% |
| 2013 | 2.08 Million USD | 280882.24% |
| 2012 | 743.36 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 26.43 Million USD | -8.14% |
| 2024 Q1 | 28.77 Million USD | -18.19% |
| 2023 Q1 | 35.18 Million USD | 5.6% |
| 2023 FY | 35.17 Million USD | 5.57% |
| 2023 Q4 | 35.17 Million USD | -2.21% |
| 2023 Q3 | 35.97 Million USD | 5.17% |
| 2023 Q2 | 34.2 Million USD | -2.8% |
| 2022 Q4 | 33.32 Million USD | 4.51% |
| 2022 Q3 | 31.88 Million USD | -2.19% |
| 2022 Q2 | 32.59 Million USD | -5.57% |
| 2022 Q1 | 34.51 Million USD | -10.62% |
| 2022 FY | 33.32 Million USD | -13.72% |
| 2021 FY | 38.62 Million USD | -32.27% |
| 2021 Q1 | 48.62 Million USD | -14.72% |
| 2021 Q3 | 41.94 Million USD | -3.91% |
| 2021 Q2 | 43.64 Million USD | -10.24% |
| 2021 Q4 | 38.62 Million USD | -7.92% |
| 2020 Q3 | 66.61 Million USD | 34.02% |
| 2020 Q1 | 42.51 Million USD | -1.1% |
| 2020 Q4 | 57.02 Million USD | -14.4% |
| 2020 FY | 57.02 Million USD | 32.65% |
| 2020 Q2 | 49.7 Million USD | 16.92% |
| 2019 FY | 42.98 Million USD | 120.83% |
| 2019 Q4 | 42.98 Million USD | 11.68% |
| 2019 Q3 | 38.48 Million USD | 4.74% |
| 2019 Q2 | 36.74 Million USD | -37.81% |
| 2019 Q1 | 59.09 Million USD | 203.58% |
| 2018 Q4 | 19.46 Million USD | 6.3% |
| 2018 Q3 | 18.31 Million USD | 23.69% |
| 2018 Q2 | 14.8 Million USD | 27.61% |
| 2018 Q1 | 11.6 Million USD | 26.16% |
| 2018 FY | 19.46 Million USD | 111.7% |
| 2017 FY | 9.19 Million USD | 2.52% |
| 2017 Q4 | 9.19 Million USD | 42.79% |
| 2017 Q1 | 7.02 Million USD | -21.72% |
| 2017 Q3 | 6.43 Million USD | -7.68% |
| 2017 Q2 | 6.97 Million USD | -0.67% |
| 2016 FY | 8.96 Million USD | 130.55% |
| 2016 Q2 | 4.97 Million USD | 21.58% |
| 2016 Q1 | 4.09 Million USD | 5.17% |
| 2016 Q4 | 8.96 Million USD | 39.21% |
| 2016 Q3 | 6.44 Million USD | 29.53% |
| 2015 Q2 | 2.79 Million USD | 403.92% |
| 2015 Q1 | 554.77 Thousand USD | -24.83% |
| 2015 Q4 | 3.89 Million USD | 80.1% |
| 2015 FY | 3.89 Million USD | 427.11% |
| 2015 Q3 | 2.16 Million USD | -22.73% |
| 2014 Q4 | 738.04 Thousand USD | 20.26% |
| 2014 Q2 | 1.08 Million USD | 10.82% |
| 2014 Q1 | 978.42 Thousand USD | -53.16% |
| 2014 FY | 738.04 Thousand USD | -64.67% |
| 2014 Q3 | 613.68 Thousand USD | -43.4% |
| 2013 FY | 2.08 Million USD | 280882.24% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 2.08 Million USD | 0.0% |
| 2012 FY | 743.36 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 94.363% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 72.104% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 94.305% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 86.712% |
| bluebird bio, Inc. | 424.62 Million USD | 91.716% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 48.84% |
| Imunon, Inc. | 8.53 Million USD | -312.372% |
| Editas Medicine, Inc. | 150.05 Million USD | 76.557% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.829% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.997% |
| Myriad Genetics, Inc. | 312.9 Million USD | 88.758% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 96.549% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 92.784% |
| Verastem, Inc. | 71.18 Million USD | 50.584% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.949% |
| Waters Corporation | 3.47 Billion USD | 98.988% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.932% |
| Biogen Inc. | 12.04 Billion USD | 99.708% |
| Nektar Therapeutics | 267.04 Million USD | 86.827% |
| Perrigo Company plc | 6.04 Billion USD | 99.418% |
| Dynavax Technologies Corporation | 375.02 Million USD | 90.62% |
| Illumina, Inc. | 4.36 Billion USD | 99.194% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 82.028% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 86.285% |
| Unity Biotechnology, Inc. | 37.29 Million USD | 5.671% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 98.139% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 57.326% |
| Evolus, Inc. | 209.68 Million USD | 83.224% |
| Adicet Bio, Inc. | 37.12 Million USD | 5.234% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 12.551% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.505% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 94.677% |
| FibroGen, Inc. | 585.72 Million USD | 93.994% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.285% |
| OPKO Health, Inc. | 622.47 Million USD | 94.349% |
| Homology Medicines, Inc. | 118.53 Million USD | 70.323% |
| Geron Corporation | 146.12 Million USD | 75.927% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.132% |
| Exelixis, Inc. | 678.44 Million USD | 94.815% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -75.263% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -180.654% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 85.974% |
| Zoetis Inc. | 9.29 Billion USD | 99.622% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 91.145% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 28.467% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.317% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 27.388% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.649% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 98.537% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 69.361% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.867% |
| Blueprint Medicines Corporation | 918.64 Million USD | 96.171% |
| Insmed Incorporated | 1.66 Billion USD | 97.883% |
| TG Therapeutics, Inc. | 169.08 Million USD | 79.196% |
| Incyte Corporation | 1.59 Billion USD | 97.791% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 97.033% |